|
Abstract Objective To evaluate the impact of combined therapy with bezafibrate and atorvastatin on short- and long- term outcomes of patients with both acute coronary syndromes (ACS) and diabetes mel itus (DM). Methods 480 patients with ACS and DM were enrol ed. Of them, 162 cases were treated with atorvastatin and bezafibrate (observation group) and 318 cases were treated with atorvastatin (control group). 30- day major adverse cardiovascular events (MACEs), 30- day re- hospitalization rate and 1- year mortality were recorded. Results The 30- day MACEs, 30- day rehospitalization rate and 1- year mortality were 8%, 13.0% and 3.7%, respectively, in observation group, significantly lower than 15.7%, 22.6%and 8.8%in control group( al P<0.05). Multivariate analysis showed that combined therapy with atorvastatin and bezafibrate reduced the risk of 30- day MACEs after ACS (OR=0.57 , 95% CI 0.35~0.93). Conclusion Combination therapy with atorvastatin and bezafibrate may contribute to improve short- and long- term outcomes of DM patients after ACS.
|
|
|
|
|
|
